IMMP Immutep LTD ADR

$IMMP I understand the frustration behind some of the bearish posts here. Many are probably long term holders who became more bearish as the situation evolved over the past year or two. I don’t blame anyone, biotech is inherently risky and the outcome hasn’t been what many shareholders expected. That said, at the current valuation, I believe Immutep is grossly mispriced relative to the potential value of its underlying assets. That’s why I continue to think a strategic transaction, whether a partnership, licensing deal or outright acquisition with CVRs could be in play. We’ll know when we know. Until then, I’m watching the developments rather than trying to predict the outcome.

$IMMP they will get another 180 days, they just need to switch to the nasdaq capital market designation, which has no impact on trading or anything else, it’s just a category. They have done it before in the past. The reg trial for hnscc only has to be very small. They get approval and can start selling and follow up with a confirmatory trial. There will be news before April and they will get above $1. What some are missing is that they have learned important stuff from the trial. Now knowing the importance of the n-glycan structure (which effects binding) they not only know how to verify but possibly how to improve the efficacy.

$IMMP here you go pumpers! Right now we can easily update the pretty accurate price prevision I gifted you one year ago: Current SP .29; r/s gives 5.08 with the usual 30% market’s slash gives 4 bucks; Diluition (they need it to stay alive) around 50% discount (the just got a failure) gives SP at 2 bucks. Mister Market than will bring it at half the offering price, or less. Gives from 1 to .75 bucks. It gives half a dime pre-r/s adjusted. That’s will occur before every kinda new “milestone” release.

$IMMP Congrats to all longs here. There might can be a shift in confidence now. They actually say that Efti does work. Great news and let's go IMMUTEP!

$IMMP Immutep is changing its American Depositary Shares (ADS) ratio from 1 ADS = 10 ordinary shares to 1 ADS = 200 ordinary shares.

$IMMP 38M market cap if they dilute they will increase shares by 50-200%. GL # savewhatyoucan

$IMMP — Immutep just picked up an FDA Orphan Drug Designation for its program in soft-tissue sarcoma, which immediately brought a lot more attention to the ticker. Orphan designation doesn’t prove the drug works or guarantee approval, but it can provide development incentives and regulatory benefits for therapies targeting rare diseases. The designation is important — now the clinical data needs to justify the excitement.

$IMMP Giving it max pain before any meaningful good news. Classic market maker games. Nothing to do but endure the volatility, the payoff could be sweet as I think the thesis will ultimately play out.

$IMMP Will I regret not adding here? Probably. But I’m going to wait for the post split action. The current market cap is ridiculous relative to what this company has and if the brains behind this company are as sharp as I think they are, I wouldn’t be surprised to see a gap up coming. I’m certain the BD team is working around the clock. What I’m interested in is what ultimately comes out of those efforts.

$IMMP Immutep Ltd. ADR Premarket Last Updated: Sep 11, 2026 at 5:44 a.m. EDT Delayed quote $ 0.3153 -0.0098 -3.01% Before Hours Volume: not even a bounce.....

$IMMP .70 (exchange rate) x 200 x .41 asx close = share price after reverse split (which is not a dilution) will be 5.74 based on asx close current price conversion is 5.26 would check tonights asx close and if increasng could see nice gain in 5 trading days

$IMMP BioNtech lung data is insane. IMMP does not work and got no chance vs BioNtech anyways.

$IMMP they will need a lot of more money for another phase 3 which might fail as well. High dilution incoming!

$IMMP more shareholder destruction on the way!! someone needs to stuff this management team in a kangaroo pouch & zip it shut🦘

$IMMP this company has had now two failed drugs, who remembers Cvac, Prima BioMed’s personalized dendritic-cell cancer vaccine targeting MUC1, was dropped as a company priority around 2015 and licensed out in 2016. It never reached major-market approval. Now the circle repeats for a 3rd??

$IMMP piece of shit SYDNEY, AUSTRALIA, Sept. 21, 2026 — Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces a change to the ratio of its American Depositary Shares (“ADSs”), which are quoted on the Nasdaq Global Market under the symbol IMMP. With effect from the commencement of trading on the Nasdaq Global Market on 28 September 2026 (US Eastern time), the ADS ratio will change from one (1) ADS representing ten (10) ordinary shares to one (1) ADS representing two hundred (200) ordinary shares. For holders of ADSs, the change has the same practical effect as a reverse split of the ADSs on the basis of one (1) new ADS for every twenty (20) ADSs held.

$IMMP Amigos 2 extremes. Over 1.4 billion shares on ASX compared to 1.6 million shares on NASDAQ. We wait for root cause analysis clarity and IMP761 MAD data and PH2 plan.

$IMMP With the latest news, some might make a 10–15% gain today, but everyone else has already been wiped out. Good job, pumpers.

$IMMP The "Bad News" Strategy: Executive departures often trigger negative or complicated market compliance issues. For example, Pete Meyers' departure immediately forced Immutep into non-compliance with ASX Listing Rule 12.7 because their audit committee dropped below three members. Companies avoid blasting these issues out through PR distribution networks to minimize negative media coverage. Pete Meyers served on the board of Immutep Limited for 12 years and 7 months. He originally joined the biotechnology company as a Non-Executive Director on February 12, 2014. During his tenure, he was also appointed Non-Executive Deputy Chairman on November 17, 2017, and additionally served as the Chair of the Audit and Risk Committee. His service officially concluded when his resignation took effect on October 2, 202

$IMMP Get REAL! IMMP is going to continue downward sub $1/share & serial dilution fundings expected! CEO is to too arrogant & DUMB to competently bring these drugs to market based on well designed trials. Current CEO has failed in HNSCC, Breast CA & NSCLC; all failed due to poorly designed trials despite active Efti IO! As an ex-IMMP investor who thankfully left before the NSCLC IA disaster, this CASSANDRA recommends ditching IMMP & joining the SLS launch party!